Tampa, FL, December 26, 2021 –(PR.com)– Mirror Biologics, Inc., a clinical stage immunotherapy company specializing in the development, manufacturing, commercialization and clinical translation of next generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases, today announced the appointment of David Fineberg, MD, MBA, as Chief Medical Officer effective January 1, 2022.
Dr. Fineberg brings to the Company more than 18 years’ experience in the pharmaceutical industry with extensive experience in clinical development, regulatory affairs, pharmacovigilance and quality systems. Dr. Fineberg will oversee global clinical development activities for the patented “off-the-shelf,” non-genetically manipulated patented T cell product, AlloStim®, as well as managing the launch of new indications and future generations of this drug. Initial focus will be on accelerating current late stage clinical trials…
